Loading clinical trials...
Loading clinical trials...
A Study to Assess the Anamnestic Immune Response 4 to 8 Years After a Primary Vaccination Series With HBVAXPRO
To assess the safety and immunogenicity of a booster dose of hepatitis B vaccine in children who have received a 3-dose primary series of either RECOMBIVAX HB or ENGERIX-B. The primary vaccination series (was given 4 to 8 years prior to study entry and consisted of a licensed hepatitis B vaccine product (either RECOMBIVAX HB or ENGERIX-B). The booster dose given in this study will be either an investigational Merck product (Modified Process Hepatitis B Vaccine) or licensed ENGERIX-B vaccine.
Age
4 - 8 years
Sex
ALL
Healthy Volunteers
Yes
Start Date
September 1, 2006
Primary Completion Date
June 1, 2008
Completion Date
June 1, 2008
Last Updated
April 12, 2017
1,478
ACTUAL participants
Comparator: Modified Process Hepatitis B Vaccine
BIOLOGICAL
Comparator: Comparator: ENGERIX-B
BIOLOGICAL
Lead Sponsor
Merck Sharp & Dohme LLC
NCT07024641
NCT06671093
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07275554